These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33359200)

  • 1. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
    Gue YX; Spinthakis N; Egred M; Gorog DA; Farag M
    Am J Cardiol; 2021 Mar; 142():147-151. PubMed ID: 33359200
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
    Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulants: What is new and what is the standard?
    Lesko LJ
    Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
    Krumme AA; Pawar A; Schneeweiss S; Glynn RJ; Choudhry NK; Kulldorff M; Ortiz AS; Avorn J; Gagne JJ
    J Comp Eff Res; 2018 Jan; 7(1):57-66. PubMed ID: 29264930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Oldgren J
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review.
    Sedhom R; Abdelmaseeh P; Megaly M; Asinger R
    Am J Med; 2020 Nov; 133(11):1266-1273.e6. PubMed ID: 32565258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anticoagulation for patients with non-valvular atrial fibrillation].
    Mizoguchi T; Yasaka M
    Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

  • 12. New oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Holden A; Azimi N; Forest CP
    JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
    Eek AK; Øie E; Granas AG
    Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Large studies of NOAC shows good and safe stroke protection].
    Hijazi Z; Oldgren J
    Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation Therapy and NOACs in Heart Failure.
    Thomas I; EncisoSilva J; Schlueter M; Greenberg B
    Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.